Journal of Clinical Epidemiology
Volume 50, Issue 12 , Pages 1311-1318 , December 1997

The Powerful Placebo Effect: Fact or Fiction?

  • Gunver S Kienle

      Affiliations

    • Institut für Angewandte Erkenntnistheorie und Medizinische Methodologie, D-79112 Freiburg, Germany
    • Corresponding Author InformationDr. med. Gunver S. Kienle, Institut für angewandte Erkenntnistheorie und medizinische Methodologie, Muselgasse 10, D-79112 Freiburg, Germany
    • ,
  • Helmut Kiene

      Affiliations

    • Institut für Angewandte Erkenntnistheorie und Medizinische Methodologie, D-79112 Freiburg, Germany

,Accepted 20 August 1997.

References 

  1. Beecher HK. The powerful placebo. J Am Med Assoc. 1955;159(17):1602–1606
  2. Diehl HS. Medicinal treatment of the common cold. J Am Med Assoc. 1953;101:2042–2049
  3. Evans W, Hoyle C. The comparative value of drugs used in the continuous treatment of angina pectoris. Quart J Med. 1933;7:311–338
  4. Jellinek EM. Clinical tests on comparative effectiveness of analgesic drugs. Biometrics. 1946;2(5):87–91
  5. Gay LN, Carliner PE. The prevention and treatment of motion sickness. Bull Johns Hopkins Hosp. 1949;84:470–487
  6. Travell J, Rinzler SH, Bakst H, Benjamin ZH, Bobb A. Comparison of effects of alpha-tocopherol and a matching placebo on chest pain in patients with heart disease. Ann New York Acad Sci. 1949;52:345–353
  7. Greiner Th , Gold H, Cattell M, Travell J, et al.  A method for the evaluation of the effects of drugs on cardiac pain in patients with angina of effort. A study of khellin (visammin). Am J Med. 1950;9:143–155
  8. Keats AS, Beecher HK. Pain relief with hypnotic doses of barbiturates and a hypothesis. J Pharmacol Exp Ther. 1950;100:1–13
  9. Keats AS, D'Alessandro GL, Beecher HK. A controlled study of pain relief by intravenous procaine. J Am Med Assoc. 1951;147:1761–1763
  10. Beecher HK, Deffer PA, Fink FE, Sullivan DB. Field use of methadone and levo-iso-methadone in a combat zone. U S Armed Forces Med J. 1951;2:1269–1276
  11. Hillis BR. The assessment of cough-suppressing drugs. Lancet. 1952;21(June):1230–1235
  12. Beecher HK, Keats AS, Mosteller F, Lasagna L. The effectiveness of oral analgesics (morphine, codeine, acetylsalicylic acid) and the problem of placebo “reactors” and “non-reactors.”. J Pharmacol & Exper Therap. 1953;109:393–400
  13. Wolf S, Pinsky RH. Effects of placebo administration and the occurrence of toxic reactions. J Am Med Assoc. 1954;155:339–341
  14. Lasagna L, Mosteller F, Felsinger JM, Beecher HK. A study of the placebo response. Am J Med. 1954;16:770–779
  15. Gravenstein JS, Devloo RA, Beecher HK. Effect of antitussive agents on experimental and pathological cough in man. J Appl Physiol. 1954;7:119–139
  16. Lasagna L, Felsinger JM, Beecher HK. Drug-induced mood changes in man. 1. Observations on healthy subjects, chronically ill patients, and “postaddicts.”. J Am Med Assoc. 1955;157(12):1006–1020
  17. Netter P, Classen W, Feingold E. Das Placeboproblem. In:  Dölle W,  Müller-Oerlinghausen B,  Schwabe U editor. Grundlagen der Arzneimitteltherapie–Entwicklung, Beurteilung und Anwendung von Arzneimitteln. Mannheim, Wien, Zürich: Wissenschaftsverlag; 1986;p. 355–366
  18. Roberts AH, Kewman DG, Mercier L, Hovell M. The power of nonspecific effects in healing (Implications for psychosocial and biological treatments). Clin Psychol Rev. 1993;13:375–391
  19. Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE. The importance of placebo effects in pain treatment and research. J Am Med Assoc. 1994;271(20):1609–1614
  20. Bodem SH. Bedeutung der Placebowirkung in der praktischen Arzneitherapie. Pharm Ztg. 1994;139(51/52):9–19
  21. Kienle GS. Der sogenannte Placeboeffekt; Illusion, Fakten, Realität. Stuttgart, New York: Schattauer Verlag GmbH; 1995.
  22. Kienle GS, Kiene H. Placebo effect and placebo concept (A critical methodological and conceptual analysis of reports on the magnitude of the placebo effect). Altern Ther Health Med. 1996;2(6):39–54Reprint from: Kienle GS, Kiene H. Placeboeffekt und Placebokonzept—eine kritische methodologische und konzeptionelle Analyse von Angaben zum Ausmaß des Placeboeffekts. Forsch Komplementärmed 1996; 3: 121–138
  23. In:  White L,  Tursky B,  Schwartz GE editor. Placebo—Theory, Research, and Mechanisms. New York, London: Guilford Press; 1985;
  24. Hornung J. Was ist ein Placebo? Die Bedeutung einer korrekten Definition für die klinische Forschung. Forsch Komplementärmed. 1994;1:160–165
  25. Gøtzsche PC. Is there logic in the placebo?. Lancet. 1994;344:925–926
  26. Whitney CW, Von Korff M. Regression to the mean in treated versus untreated chronic pain. Pain. 1992;50:281–285
  27. Deyo RA. Practice variations, treatment fads, rising disability. Spine. 1993;18(15):2153–2162
  28. LeRoy GV. The effectiveness of the xanthine drugs in the treatment of angina pectoris. J Am Med Assoc. 1941;116(10):921–925
  29. Dyken M, White PT. Evaluation of cortisone in the treatment of cerebral infarction. J Am Med Assoc. 1956;162(17):1531–1534
  30. McDonald C, Mazzuca S, McCabe G. How much of the placebo `effect' is really statistical regression?. Stat Med. 1983;2:417–427
  31. Lichstein J, DeCosta Mayer J, Hauch EW. Efficacy of methantheline (banthine) bromide in therapy of the unstable colon. J Am Med Assoc. 1955;25(June):634–637
  32. Wells RE. Use of reserpine (Serpasil) in the management of chronic alcoholism. J Am Med Assoc. 1957;163(6):426–429
  33. Blomberg LH. Treatment of disseminated sclerosis with active and inactive drugs. Lancet. 1957;1:431–432
  34. Coe WS, Best MM, Kinsman JM. Veratrum viride in the treatment of hypertensive vascular disease. J Am Med Assoc. 1950;143(1):5–7
  35. Roberts AH. The powerful placebo revisited: The magnitude of nonspecific effects. Mind/Body Medicine 1995; March; 1–10.
  36. Sackett DL. Randomized trials in individual patients. In:  Antes G,  Edler L,  Holle R,  Köpcke W,  Lorenz R,  Windeler J editor. Biometrie und unkonventionelle Medizin. Münster–Hiltrup: Landwirtschaftsverlag GmbH; 1995;p. 19–33
  37. Kiene H. A critique of the double-blind clinical trial. Parts 1 + 2. Altern Ther Health Med. 1996;2(1):74–80and 1996; 2(2): 59–64. [Reprint from: Kiene H. Kritik der klinischen Doppelblindstudie. MMW-Taschenbuch. München: MMW Medizin; 1993: 35
  38. Barber TX. The effects of “hypnosis” on pain. Psychosom Med. 1963;25:303–333
  39. Clark WC. Sensory-decision theory analysis of the effect on the criterion for pain and thermal sensitivity. J Abnorm Psychol. 1969;74(3):363–371
  40. Fordyce WE, Lansky D, Calsyn DA, Shelton JL, Stolov WC, Rock DL. Pain measurement and pain behavior. Pain. 1984;18:53–69
  41. Tedeschi JT, Schlenker BR, Bonoma TV. Cognitive dissonance (Private ratiocination or public spectacle?). Amer Psychol. 1971;26:685–695
  42. Ader R. Conditioned Immunopharmacological Effects in Animals (Implications for a Conditioning Model of Pharmacotherapy). In:  White L,  Tursky B,  Schwartz GE editor. Placebo—Theory, Research, and Mechanisms. New York: Guilford Press; 1985;
  43. Peck C, Coleman G. Implications of placebo theory for clinical research and practice in pain management. Theor Med. 1991;12:247–270
  44. Voudouris NJ, Peck CL, Coleman G. The role of conditioning and verbal expectancy in the placebo response. Pain. 1990;43:121–128
  45. Wall PD. Pain and the placebo response. Ciba Found Symp. 1993;174:187–211
  46. Wickramasekera I. A conditioned response model of the placebo effect (Predictions from the model). In:  White L,  Tursky B,  Schwartz GE editor. Placebo—Theory, Research, and Mechanisms. New York: Guilford Press; 1985;
  47. Suchman AL, Ader R. Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther. 1992;52(4):372–377
  48. Iacono P, Drici MD, De Lunardo C, Salimbeni B, Lapalus P. Placebo effect in cardiovascular clinical pharmacology. Int J Clin Pharmacol Res. 1992;XII(2):53–56
  49. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Health. 1995;8:311–315
  50. Weber MA, Neutel JM, Smith DHG. Controlling blood pressure throughout the day (Issues in testing a new anti-hypertensive agent). J Hum Hypertens. 1995;9(Suppl. 5):29–35
  51. Report of Research Council Working Party on mild to moderate hypertension . Randomized controlled trial of treatment for mild hypertension (Design and pilot trial). Br Med J. 1977;1:1437–1440
  52. Schindel L. Placebo und Placebo-Effekte in Klinik und Forschung. Arzneimittelforschung. 1967;17:892–918
  53. Beecher HK. Die Placebowirkung als unspezifischer Wirkungsfaktor im Bereich der Krankheit und der Krankenbehandlung. In:  Gross F,  Beecher HK editor. Placebo—das universelle Medikament? Paul-Martini-Stiftung der Medizinisch Pharmazeutischen Studiengesellschaft e.V. Mainz: Eggebrecht-Presse; 1984;
  54. Wolf S. The pharmacology of placebos. Pharmacol Rev. 1959;11:689–704
  55. Hollister L. Placebology (Sense and nonsense). Curr Ther Res. 1960;2(9):477–483
  56. Veterans Administration. Minutes of the Fifth Streptomycin Conference; Knickerbocker Hotel, Chicago, Illinois; April 15–18, 1948.
  57. Green DM. Pre-existing conditions, placebo reactions, and “side effects.”. Ann Intern Med. 1964;60(2):255–265
  58. Reidenberg MM, Lowenthal DT. Adverse nondrug reactions. N Eng J Med. 1968;279(13):678–679
  59. Long DM, Uematsu S, Kouba RB. Placebo responses to medical device therapy for pain. Stereotact Funct Neurosurg. 1989;53:149–156
  60. Ernst E, Resch KI. Concept of true and perceived placebo effects. Br Med J. 1995;311:551–553
  61. Ho KH, Hashish I, Salmon P, Freeman R, Harvey W. Reduction of post-operative swelling by a placebo effect. J Psychosom Res. 1988;32(2):197–205
  62. Hashish I, Harvey W, Harris M. Anti-inflammatory effects of ultrasound therapy (Evidence for a major placebo effect). Br J Rheumatol. 1986;25:77–81
  63. Ross S, Krugman A, Lyerly S, Clyde D. Drugs and placebos (A model design). Psychol Rep. 1962;10:382–392
  64. Marlatt A, Rohsenow D. Cognitive processes in alcohol use (Expectancy and the balanced placebo design). Adv Subst Abuse. 1980;1:159–199
  65. Shapiro AK, Shapiro E. Patient-provider relationships and the placebo effect. In:  Matarazzo JD,  Weiss SM,  Herd JA,  Miller NE editor. Behavioral Health (A Handbook of Health Enhancement and Disease Prevention). New York: Wiley-Interscience; 1984;p. 371–383
  66. Peek CJ. A critical look at the theory of placebo. Biofeedback Self-Regul. 1977;2:327–335
  67. Grünbaum A. Explications and implications of the placebo concept. In:  White L,  Tursky B,  Schwartz GE editor. Placebo—Theory, Research, and Mechanisms. New York: Guilford Press; 1985;
  68. Kirsch I, Weixel LJ. Double blind versus deceptive administration of a placebo. Behav Neurosci. 1988;102(2):319–323
  69. Hornung J. Zur Problematik der Doppelblindstudien. Therapeutikon. 1989;3:696–701
  70. Kirsch I, Rosadino MJ. Do double-blind studies with informed consent yield externally valid results?. Psychopharmacology. 1993;110:437–442

PII: S0895-4356(97)00203-5

Journal of Clinical Epidemiology
Volume 50, Issue 12 , Pages 1311-1318 , December 1997

Article Tools